INSIGHTS ON CELL & GENE OUTSOURCING ISSUES
-
![Picture2]( "How To Fast-Track Your Oral Solid Dose To Phase 1")
How To Fast-Track Your Oral Solid Dose To Phase 1A strategic approach accelerates oral solid dose development by uniting molecular analysis, solubility improvement, formulation design, manufacturing efficiency, and stability testing to reach Phase 1 faster.
-
![GettyImages-2217581928 manufacturing, production]( "Practical USP <1665>/<665> Guide To E&L Risk Assessment")
Practical USP <1665>/<665> Guide To E&L Risk AssessmentA practical USP <1665> and <665> framework helps manufacturers evaluate and manage extractables and leachables risk, supporting quality, safety, and regulatory compliance.
-
![GettyImages-139602926 labeling, packaging, pharma]( "USP <382> Functional Suitability & CCI Testing")
USP <382> Functional Suitability & CCI TestingUSP <382> testing assesses packaging integrity, safety, and performance using deterministic CCIT and functional evaluations to support validation and regulatory submissions.
-
![GettyImages-2178829362-glp-1-protein-3d-render]( "The Adenovirus Revolution In Cancer Treatment")
The Adenovirus Revolution In Cancer TreatmentAdenoviruses are being reimagined as powerful tools for oncolytic cancer therapy, using their immunogenicity, tumor selectivity, and synergy with immunotherapy to drive new clinical progress.
-
![GettyImages-1309776504-viral-inspection-laboratory-scientists]( "Viral Vector Development And Manufacturing Services")
Viral Vector Development And Manufacturing ServicesSupported by a global site network, supply chain infrastructure, and deep technical and regulatory expertise, we provide a coordinated approach to accelerate your therapy’s journey.
-
![GettyImages-2187764040-cell-culture-testing-manufacturing-in-lab]( "From Promise To Patients: Smarter Pathways To Scale In Cell And Gene Therapy Manufacturing")
From Promise To Patients: Smarter Pathways To Scale In Cell And Gene Therapy ManufacturingAs the field evolves, the strategies developers choose may prove just as influential as the therapies themselves in determining how quickly innovation reaches patients.
-
![GettyImages-2165310987-chromosome-nucleotide-gene]( "Get To Know: Oligonucleotide Synthesis Workflow")
Get To Know: Oligonucleotide Synthesis WorkflowDiscover the basics of synthetic oligonucleotides, from their building blocks to stepwise synthesis and purification.
-
![Jan 2026 CDMO]( "January 2026 — CDMO Opportunities And Threats Report")
January 2026 — CDMO Opportunities And Threats ReportEach month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
![GettyImages-2187764040-cell-culture-testing-manufacturing-in-lab]( "Smart Scaling For Cell And Gene Therapies")
Smart Scaling For Cell And Gene TherapiesTo meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.
-
![GettyImages-1487365113-scientist-with-gloves-tablet-in-hands-microscope-lab]( "AI And Digital Maturity In Contract Development And Manufacturing")
AI And Digital Maturity In Contract Development And ManufacturingExplore how CDMOs are navigating digital maturity, where AI is driving real operational gains, and why sponsor expectations are accelerating the push toward digital readiness.
